4D Molecular Therapeutics (FDMT) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Prime Medicine is the larger company by market cap ($707.4 million vs $695.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | FDMT | PRME |
|---|---|---|
| Share price | $12.59 | $3.90 |
| Market cap | $695.52M | $707.37M |
| 1-day change | +0.24% | +11.43% |
| 5-year return | -53.92% | — |
| EPS (TTM) | $-2.63 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $6.85 |
| 52-week low | $6.96 | $2.67 |
| Distance from 52-week high | -25.63% | -43.07% |
| Average volume | 924.05K | 3.32M |
| Shares outstanding | 55.24M | 181.38M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
FDMT vs PRME FAQ
Which is bigger, 4D Molecular Therapeutics or Prime Medicine?
Prime Medicine (PRME) is larger, with a market capitalization of $707.37M compared with $695.52M for 4D Molecular Therapeutics (FDMT).
Are 4D Molecular Therapeutics and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.